Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azvudine Prevention in Household Contacts of SARS-CoV-2
NCT05633433Phase 3Unknown
- Sponsor
- Henlius
- Start
- Dec 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of azvudine in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Henlius. Primary endpoint: Incidence of SARS-CoV-2 infection at 7 days. Status: unknown.
02
Drugs
azvudine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05633433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05633433.